(8)
R
EFERENCES
[1]
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009 Jul 25;374(9686):324-39.
[2]
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe
in 2008. Eur J Cancer. 2010 Mar;46(4):765-81.
[3]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of
cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Jun 17.
[4]
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working
Group. International uniform response criteria for multiple myeloma. Leukemia. 2006
Sep;20(9):1467-73. Epub 2006 Jul 20. Erratum in: Leukemia. 2007 May;21(5):1134. Leukemia. 2006 Dec;20(12):2220.
[5]
Durie BG, Salmon SE. Cellular kinetics staging, and immunoglobulin synthesis in multiple
myeloma. Annu Rev Med. 1975;26:283-8.
[6]
Kyle RA, Kumar S. The significance of monoclonal gammopathy of undetermined significance.
Haematologica. 2009 Dec;94(12):1641-4.
[7]
Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–87.
[8]
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up
of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc. 2004 Jul;79(7):859-66.
[9]
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined
significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009
May 28;113(22):5412-7. [10]
Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2011 Feb 28;6:249-74. [11]
Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002 Aug 15;100(4):1417-24.
[12]
Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, Grange MJ, Monconduit M, Bastard C. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different
diseases. Leukemia. 1998 Jun;12(6):960-9.
[13]
Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ.
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010 Oct 14;116(15):e56-65. Epub 2010 Jul 8.
[14]
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation:
an early and unifying pathogenic event in multiple myeloma. Blood. 2005 Jul 1;106(1):296-303.
Epub 2005 Mar 8. [15]
Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Dávila R, González-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. The
recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003 Oct 1;102(7):2562-7.
[16]
Tonon G. Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 2007 Dec;21(6):985-1006, vii.
[17]
Munshi NC. Plasma cell disorders: an historical perspective. Hematology 2008; 2008: 297. [18]
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the
impact of novel therapies. Blood 2008;111: 2516–20.
[19]
Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–87.
[20]
Engelhardt M, Kleber M, Udi J, Wäsch R, Spencer A, Patriarca F, Knop S, Bruno B, Gramatzki M, Morabito F, Kropff M, Neri A, Sezer O, Hajek R, Bunjes D, Boccadoro M, Straka C, Cavo M, Polliack A, Einsele H, Palumbo A. Consensus statement from European experts on the diagnosis,
management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010 Aug;51(8):1424-43.
[21]
Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008 Jan 20;26(3):480-92.
[22]
Meyerding HW. Multiple myeloma. Radiology 1925; 5:132-136. [23]
Eriksson M, Hållberg B. Familial occurrence of hematologic malignancies and other diseases in
multiple myeloma: a case-control study. Cancer Causes Control. 1992 Jan;3(1):63-7.
[24]
Brown LM, Linet MS, Greenberg RS, Silverman DT, Hayes RB, Swanson GM, Schwartz AG, Schoenberg JB, Pottern LM, Fraumeni JF Jr. Multiple myeloma and family history of cancer
among blacks and whites in the U.S. Cancer. 1999 Jun 1;85(11):2385-90.
[25]
Ogmundsdóttir HM, Haraldsdóttirm V, Jóhannesson GM, Olafsdóttir G, Bjarnadóttir K, Sigvaldason H, Tulinius H. Familiality of benign and malignant paraproteinemias. A
population-based cancer-registry study of multiple myeloma families. Haematologica. 2005 Jan;90(1):66-71.
[26]
Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Isgur Bergsagel K, Huiart L, Olopade OI, Sobol H, Sanger W, Hogg D, Weisenburger D. Phenotypic heterogeneity in multiple
myeloma families. J Clin Oncol. 2005 Feb 1;23(4):685-93.
[27]
Domingo-Domènech E, Benavente Y, Alvaro T, Hernández M, de Sevilla AF, de Sanjosé S. Family
clustering of blood cancers as a risk factor for lymphoid neoplasms. Haematologica. 2005
Mar;90(3):416-8. [28]
Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics
of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer. 2006 Jun 15;118(12):3095-8.
[29]
Kristinsson SY, Björkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives
of 13,896 patients with multiple myeloma in Sweden. Int J Cancer. 2009 Nov 1;125(9):2147-50.
[30]
Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, Wahlin A, Bjorkholm M, Turesson I. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree
relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009 Jul 23;114(4):791-5.
[31]
Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Björkholm M, Holm G, Yi Q.
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol. 2000
Apr;109(1):39-45. [32]
Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, Rothman N, Bernstein L, Hartge P, Morhbacher A, Coetzee SG, Salam MT, Wang W, Zadnick J, Ingles SA.
Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2285-91.
[33]
Mazur G, Bogunia-Kubik K, Wróbel T, Karabon L, Polak M, Kuliczkowski K, Lange A. IL-6 and IL-10
promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma.
Immunol Lett. 2005 Jan 31;96(2):241-6. [34]
[35]
Morgan GJ, Adamson PJ, Mensah FK, Spink CF, Law GR, Keen LJ, Roman E, Davies FE, Rollinson S, Child JA, Bidwell JL. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol. 2005 May;129(3):358-65.
[36]
Du J, Yuan Z, Zhang C, Fu W, Jiang H, Chen B, Hou J. Role of the TNF-alpha promoter
polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res 34(11): 1453-8.
[37]
Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of
multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):282-8.
[38]
Purdue MP, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M, Hosgood HD 3rd, Zahm SH, Chanock SJ, Rothman N, Baris D. Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol. 2010 Jul 23
[39]
Hosgood HD 3rd, Baris D, Zhang Y, Zhu Y, Zheng T, Yeager M, Welch R, Zahm S, Chanock S, Rothman N, Lan Q. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol. 2008 Sep;26(3):148-51.
[40]
Roddam PL, Rollinson S, O'Driscoll M, Jeggo PA, Jack A, Morgan GJ. Genetic variants of NHEJ DNA
ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002 Dec;39(12):900-5.
[41]
Hayden PJ, Tewari P, Morris DW, Staines A, Crowley D, Nieters A, Becker N, de Sanjosé S, Foretova L, Maynadié M, Cocco PL, Boffetta P, Brennan P, Chanock SJ, Browne PV, Lawler M.
Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol
Genet. 2007 Dec 15;16(24):3117-27. [42]
Hosgood HD 3rd, Baris D, Zhang Y, Berndt SI, Menashe I, Morton LM, Lee KM, Yeager M, Zahm SH, Chanock S, Zheng T, Lan Q. Genetic variation in cell cycle and apoptosis related genes and
multiple myeloma risk. Leuk Res. 2009 Dec;33(12):1609-14.
[43]
Kim HN, Kim YK, Lee IK, Lee JJ, Yang DH, Park KS, Choi JS, Park MR, Jo DY, Kim HJ. Polymorphisms
involved in the folate metabolizing pathway and risk of multiple myeloma. Am J Hematol. 2007
Sep;82(9):798-801. [44]
Lima CS, Ortega MM, Ozelo MC, Araujo RC, De Souza CA, Lorand-Metze I, Annichino-Bizzacchi JM, Costa FF. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine
synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leuk Res. 2008 Mar;32(3):401-5.
[45]
Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, Mirowski M, Robak T. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of
multiple myeloma. Leuk Res. 2009 Feb;33(2):332-5.
[46]
Maggini V, Buda G, Galimberti S, Martino A, Orciuolo E, Morabito F, Bono R, Barale R, Petrini M, Rossi AM. Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leuk Res. 2008 Jun;32(6):988-90.
[47]
Kang SH, Kim TY, Kim HY, Yoon JH, Cho HI, Yoon SS, Kang DH, Suh CW, Lee JH, Lee DS. Protective
role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol. 2008;119(1):60-4.
[48]
Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A, Spencer A. Xenobiotic gene polymorphisms and
susceptibility to multiple myeloma. Haematologica. 2004 May;89(5):628-9.
[49]
Lincz LF, Scorgie FE, Robertson R, Enno A. Genetic variations in benzene metabolism and
susceptibility to multiple myeloma. Leuk Res. 2007 Jun;31(6):759-63. Epub 2006 Sep 1.
[50]
Ortega MM, Honma HN, Zambon L, Lorand-Metze I, Costa FF, De Souza CA, Lima CS. GSTM1 and
codon 72 P53 polymorphism in multiple myeloma. Ann Hematol. 2007 Nov;86(11):815-9.
[51]
Zintzaras E, Giannouli S, Rodopoulou P, Voulgarelis M. The role of MTHFR gene in multiple
[52]
Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H.
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002 Sep
15;100(6):2263-5. [53]
Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, Dring AM, Fenton JA, Child JA, Allan JM, Morgan GJ. Polymorphic variation in GSTP1 modulates outcome following
therapy for multiple myeloma. Blood. 2003 Oct 1;102(7):2345-50.
[54]
Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Petrini M, Rossi AM. Association of folate transporter SLC19A1 polymorphisms with
the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. Leukemia. 2007 Jan;21(1):176-8.
[55]
Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Petrini M, Rossi AM. Response to chemotherapy and tandem autologous
transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. Leuk Res.
2008 Jan;32(1):49-53. [56]
Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Petrini M, Rossi AM. Association of folate transporter SLC19A1 polymorphisms with
the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. Leukemia. 2007 Jan;21(1):176-8.
[57]
Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P. Influence of genetic
polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica. 2007 Feb;92(2):277-8.
[58]
Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, Barale R, Petrini M, Rossi AM. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics. 2008 May;18(5):383-9.
[59]
Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Bladé J, Orlowski RZ. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1
are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010
Nov;89(11):1133-40. [60]
Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, Gemignani F. Genetic polymorphisms associated with outcome in multiple myeloma patients
receiving high-dose melphalan. Bone Marrow Transplant. 2010 Aug;45(8):1316-24.
[61]
Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB. No influence of the polymorphisms CYP2C19 and CYP2D6 on the
efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
BMC Cancer. 2010 Aug 4;10:404. [62]
Vangsted A, Gimsing P, Klausen TW, Nexø BA, Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome
in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J
Cancer. 2007 Mar 1;120(5):1036-45. [63]
Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U. The polymorphism IL-1beta T-31C is associated with a
longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow
Transplant. 2009 Apr;43(7):539-45. [64]
Sati HI, Greaves M, Apperley JF, Russell RG, Croucher PI. Expression of interleukin-1beta and
tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J
Haematol. 1999 Feb;104(2):350-7. [65]
[66]
Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of
new targets for myeloma therapy. Leukemia. 2009 Jan;23(1):10-24.
[67]
Gadó K, Domján G, Hegyesi H, Falus A. Role of INTERLEUKIN-6 in the pathogenesis of multiple
myeloma. Cell Biol Int. 2000;24(4):195-209.
[68]
Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F. Autologous
peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica. 2000 Jan;85(1):52-8.
[69]
Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA, Morgan GJ.
High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.
J Clin Oncol. 2000 Aug;18(15):2843-51. [70]
Aladzsity I, Kovács M, Semsei A, Falus A, Szilágyi A, Karádi I, Varga G, Füst G, Várkonyi J.
Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res. 2009 Nov;33(11):1570-3.
[71]
Villuendas G, San Millán JL, Sancho J, Escobar-Morreale HF. The -597 G-->A and -174 G-->C
polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin
Endocrinol Metab. 2002 Mar;87(3):1134-41. [72]
Walston JD, Matteini AM, Nievergelt C, Lange LA, Fallin DM, Barzilai N, Ziv E, Pawlikowska L, Kwok P, Cummings SR, Kooperberg C, LaCroix A, Tracy RP, Atzmon G, Lange EM, Reiner AP.
Inflammation and stress-related candidate genes, plasma interleukin-6 levels, and longevity in older adults. Exp Gerontol. 2009 May;44(5):350-5.
[73]
Singh MS, Michael M. Role of xenobiotic metabolic enzymes in cancer epidemiology. Methods Mol Biol. 2009;472:243-64.
[74]
Agúndez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab. 2008 Jul;9(6):520-31.
[75]
Sheweita SA, Tilmisany AK. Cancer and phase II drug-metabolizing enzymes. Curr Drug Metab. 2003 Feb;4(1):45-58.
[76]
Rundle A. Carcinogen-DNA adducts as a biomarker for cancer risk. Mutat Res. 2006 Aug 30;600(1-2):23-36. Epub 2006 Jul 5.
[77]
Nishikawa A, Mori Y, Lee IS, Tanaka T, Hirose M. Cigarette smoking, metabolic activation and
carcinogenesis. Curr Drug Metab. 2004 Oct;5(5):363-73.
[78]
Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1,
MRP1 (ABCC1) and related transporters. Toxicology. 2001 Oct 5;167(1):3-23.
[79]
Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers:
physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch. 2004 Feb;447(5):465-8.
[80]
Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1,
MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37.
[81]
Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense
and organ regeneration. J Pharmacol Exp Ther. 2009 Jan;328(1):3-9.
[82]
Abbott BL. ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells. Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72.
[83]
Abbott BL. ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol. 2003 Sep;21(3):115-30.
[84]
Shen S, Zhang W. ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci. 2010;21(1):29-53.
[85]
Ferguson LR, De Flora S. Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res. 2005 Dec 11;591(1-2):24-33.
[86]
Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP
[87]
Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through
interactions with heme. J Biol Chem. 2004 Jun 4;279(23):24218-25.
[88]
Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug
resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab. 2004
Feb;5(1):21-53. [89]
Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1,
MRP1 (ABCC1) and related transporters. Toxicology. 2001 Oct 5;167(1):3-23.
[90]
Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter
protein in cancer. IUBMB Life. 2007 Dec;59(12):752-7.
[91]
Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, Scheper RJ. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest. 2002 Feb;82(2):193-201.
[92]
Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the
multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion. 2009;80(1):36-9.
[93]
Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M. ABCB1 gene
polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis. 2009
Aug;24(8):895-905. [94]
Leal-Ugarte E, Gutiérrez-Angulo M, Macías-Gómez NM, Peralta-Leal V, Durán-González J, De La Luz Ayala-Madrigal M, Partida-Pérez M, Barros-Núñez P, Ruiz-Díaz D, Moreno-Ortiz JM, Peregrina-Sandoval J, Meza-Espinoza JP. MDR1 C3435T polymorphism in Mexican children with
acute lymphoblastic leukemia and in healthy individuals. Hum Biol. 2008 Aug;80(4):449-55.
[95]
Campa D, Pardini B, Naccarati A, Vodickova L, Novotny J, Försti A, Hemminki K, Barale R, Vodicka P, Canzian F. A gene-wide investigation on polymorphisms in the ABCG2/BRCP transporter and
susceptibility to colorectal cancer. Mutat Res. 2008 Oct 14;645(1-2):56-60.
[96]
Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD. Association of the ABCG2 C421A
polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9.
[97]
Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL. MDR1 gene
variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia.
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1172-7. [98]
Hu LL, Wang XX, Chen X, Chang J, Li C, Zhang Y, Yang J, Jiang W, Zhuang SM. BCRP gene
polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
Carcinogenesis. 2007 Aug;28(8):1740-4. [99]
Hattori H, Suminoe A, Wada M, Koga Y, Kohno K, Okamura J, Hara T, Matsuzaki A. Regulatory
polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res. 2007 Dec;31(12):1633-40.
[100]
Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, Li D. Association of multi-drug resistance gene
polymorphisms with pancreatic cancer outcome. Cancer. 2010 Oct 4.
[101]
Wang H, Jin G, Wang H, Liu G, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D. Genetic susceptibility
of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer. 2009 Feb 1;115(3):595-607.
[102]
Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, Mirowski M, Robak T. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of
multiple myeloma. Leuk Res. 2009 Feb;33(2):332-5.
[103]
Jaffe E. S. HNL, Stein H., Vardiman J. W. Pathology and Genetics of Tumours of Heamatopoietic
and Lymphoid Tissues. Lyon: IARC PRess, 2001
[104]
[105]
Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association
studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008
May;32(4):361-9. [106]
Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from
population data. Am J Hum Genet. 2001 Apr;68(4):978-89. Epub 2001 Mar 9.
[107]
Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference
and missing-data imputation. Am J Hum Genet. 2005 Mar;76(3):449-62. Epub 2005 Jan 31.
[108]
Timsit YE, Negishi M. CAR and PXR: the xenobiotic-sensing receptors. Steroids. 2007 Mar;72(3):231-46.
[109]
Köhle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate
transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor.
Biochem Pharmacol. 2009 Feb 15;77(4):689-99. [110]
Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide
polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos. 2008 Jan;36(1):169-81.
[111]
Ikeda S, Kurose K, Jinno H, Sai K, Ozawa S, Hasegawa R, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Tamura T, Yamamoto N, Kunitoh H, Yamada Y, Ohe Y, Shimada Y, Shirao K, Kubota K, Minami H, Ohtsu A, Yoshida T, Saijo N, Saito Y, Sawada J.
Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab. 2005 Sep-Oct;86(1-2):314-9.
[112]
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Polymorphisms in genes of the steroid receptor superfamily modify
postmenopausal breast cancer risk associated with menopausal hormone therapy. Int J Cancer.
